EGFR and neoplasm: Although both EGFR-TKIs and PD-1/PD-L1 inhibitors can regulate tumor lipid metabolism, our results suggest that the mechanisms of lipid metabolism regulation may differ, leading to significant differences in lipid metabolism between the two treatments.